AVTR · Avantor, Inc.
Price
Snapshot
50 fields · last close| Market Cap | $10.60B |
| P/E | — |
| Float | 651.2M |
| Beta | 0.95 |
| Volatility 30D | 30.1% |
| Exchange | NYSE |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 71.4 |
| Price | 15.31 |
| Change | −2.17% |
| Prev Close | 15.65 |
| Open | 15.88 |
| Day Low | 15.45 |
| Day High | 16.19 |
| Avg Vol | 12 |
| Avg $ Vol | $185.5M |
| 52W High | 17.45 |
| 52W Low | 7.26 |
| 52W Pos | 79.0% |
| From High | −12.26% |
| From Low | +110.74% |
| Max DD 1Y | −41.19% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −5.96% |
| SMA 50 | −1.64% |
| SMA 200 | +36.11% |
| RSI (14) | 44.0 |
| Vol 90D | 43.0% |
| Vol 1Y | 42.9% |
| 1Y Range | 7–17 |
| Daily bars | 900 |
| Perf Week | −6.23% |
| Perf Month | +1.43% |
| Perf Quarter | +18.74% |
| Perf Half Y | +85.65% |
| Perf Year | +33.99% |
| Perf YTD | +33.60% |
| Prev Day | −2.17% |
| Clavix | B- |
| Debt / Eq | 0.71 |
| Curr Ratio | 1.78 |
| Int Cover | -1.8× |
| FCF Margin | 7.5% |
| Rev Growth | −3.4% |
| Profit | Unprofitable |
| Leverage | Moderate |
| Sector rank | 12 / 19 |
Clavix risk grade
regraded every trading dayAVTR grades B-, 71.4 of 100. Steadiest on News Sentiment (66), most exposed on Price Stability (54, mixed). 2 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 12 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| AVTR | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.95 | 1.16 |
| 30-day realized volatilityannualized, from daily closes | 30.1% | 30.3% |
| Max drawdown, past yearworst peak-to-trough fall | −41.2% | — |
| Typical daily movemedian absolute daily change | 1.37% | — |
| Days beyond ±3%of the last 252 sessions | 53 (21%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| AVTR | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.95 | 1.16 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 53% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| AVTR | |
|---|---|
| 1 week | −6.2% |
| 1 month | +1.4% |
| Year to date | +33.6% |
| 1 year | +34.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| AVTR | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 5 Aug |
| Average score0 most bearish, 100 most bullish | 68 |
| Bullish · bearisharticles above 60 · below 40 | 25 · 1 |
| Directionarticles whose tone is improving vs worsening | 25 ↑ 1 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| AVTR | |
|---|---|
| Revenue growthyear over year | −3.4% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openOn October 30, 2026, Avantor’s compensation committee approved a special long-term incentive award for Claudius Sokenu, its Executive Vice President, Chief Legal and Compliance Officer and Secretary. He was granted 62,305 restricted stock units, rights to receive Avantor shares after vesting, which vest in equal installments over three years provided he remains employed.
Avantor (AVTR) returned to organic revenue growth, growth from its ongoing business, excluding currency changes and acquisitions, in the third quarter of 2026. The improvement was led by accelerating performance in VWR Distribution & Services and a return to growth in Bioscience & Medtech Products.
Avantor reported $1.698 billion of revenue for Q3 2026, with sales excluding acquisition, divestiture and currency effects rising 5.2%. The return to organic revenue growth was led by accelerating performance in VWR Distribution & Services and a return to growth in Bioscience & Medtech Products.
Avantor reported third-quarter 2026 net sales of $1.70 billion, up 5.2% organically (adjusted for currency and acquisition effects), with adjusted earnings of $0.22 per share and a 15.1% adjusted EBITDA margin, meaning profit before interest, taxes, depreciation and amortization as a share of sales. VWR Distribution & Services posted 5.8% organic growth and drove the quarter, while Avantor raised its fiscal 2026 targets for organic revenue growth, adjusted earnings per share and free cash flow.
Avantor reported third-quarter earnings of $0.22 per share, above the Zacks consensus estimate of $0.21 and equal to $0.22 a year earlier. The headline also says revenue exceeded estimates, but the article provides no revenue figure.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| QGEN | QIAGEN N.V. | B+ | $10.50B | 25.58 | 0.57 | Compare |
| RGEN | Repligen Corporation | B- | $11.39B | 232.35 | 1.17 | Compare |
| TECH | Bio-Techne Corporation | A | $11.42B | 62.75 | 1.26 | Compare |
| BRKR | Bruker Corporation | C+ | $9.72B | — | 1.26 | Compare |
| TXG | 10x Genomics, Inc. | D+ | $8.51B | — | 2.07 | Compare |
| TEM | Tempus AI, Inc. | D- | $13.79B | — | 2.50 | Compare |
| CRL | Charles River Laboratories International, Inc. | B- | $15.58B | — | 1.34 | Compare |
| RVTY | Revvity, Inc. | B | $17.79B | 75.29 | 1.06 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.